Research: Idraparinux not as good as standard therapy

09/12/2007 | HealthDay News

Sanofi-Aventis' anti-clot drug idraparinux was found to be effective for the treatment of deep vein thrombosis and for the long-term prevention of blood clots, but it failed to measure up to the standard treatment for potentially life-threatening pulmonary embolisms, three studies report. The studies also showed long-term use of the drug increases the rate of severe bleeding complications more than standard therapy, scientists revealed.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX